- Home
- FEMY vs COEP Comparison
FEMY vs COEP Comparison
Compare FEMY & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- COEP
- Stock Information
- Founded
- FEMY 2004
- COEP 2017
- Country
- FEMY United States
- COEP United States
- Employees
- FEMY N/A
- COEP N/A
- Industry
- FEMY Medical/Dental Instruments
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FEMY Health Care
- COEP Health Care
- Exchange
- FEMY Nasdaq
- COEP Nasdaq
- Market Cap
- FEMY 29.9M
- COEP 27.4M
- IPO Year
- FEMY 2021
- COEP N/A
- Fundamental
- Price
- FEMY $0.83
- COEP $10.77
- Analyst Decision
- FEMY Strong Buy
- COEP
- Analyst Count
- FEMY 3
- COEP 0
- Target Price
- FEMY $8.67
- COEP N/A
- AVG Volume (30 Days)
- FEMY 158.0K
- COEP 56.9K
- Earning Date
- FEMY 08-07-2025
- COEP 08-15-2025
- Dividend Yield
- FEMY N/A
- COEP N/A
- EPS Growth
- FEMY N/A
- COEP N/A
- EPS
- FEMY N/A
- COEP N/A
- Revenue
- FEMY $1,699,232.00
- COEP $62,874.00
- Revenue This Year
- FEMY $283.83
- COEP N/A
- Revenue Next Year
- FEMY $161.03
- COEP N/A
- P/E Ratio
- FEMY N/A
- COEP N/A
- Revenue Growth
- FEMY 61.97
- COEP N/A
- 52 Week Low
- FEMY $0.69
- COEP $2.31
- 52 Week High
- FEMY $1.80
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- FEMY 37.62
- COEP 59.53
- Support Level
- FEMY $0.91
- COEP $11.30
- Resistance Level
- FEMY $0.93
- COEP $12.71
- Average True Range (ATR)
- FEMY 0.04
- COEP 0.89
- MACD
- FEMY -0.01
- COEP 0.18
- Stochastic Oscillator
- FEMY 5.12
- COEP 54.39
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.